Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing sulopenem oral to be an oral penem available in the U.S. and an oral and intravenous (IV) branded penem available globally. The objective of Co.'s sulopenem program is to deliver to patients an oral and IV formulation of sulopenem approved in the U.S. and Europe for the treatment of infections due to resistant gram-negative pathogens. Co. has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. The ITRM stock yearly return is shown above.
The yearly return on the ITRM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ITRM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|